Robert W. Fairbairn

September 27, 2026

BMEZ Q2 2026 Commentary Released on SeekingAlpha. A Q2 2026 commentary for BlackRock Health Sciences Term Trust was published on SeekingAlpha. The report reviews the trust’s recent performance and outlook. This update adds fresh information for investors as the share trades near its 52‑week low.

October 1, 2026

BlackRock CEFs Announce Estimated Sources of Distributions. BlackRock has announced the estimated sources of distributions for certain closed-end funds, including the Science and Technology Term Trust. This disclosure provides transparency on how payouts are generated, which is a key consideration for income-focused holders. The fund's low trailing P/E of 1.9 suggests a valuation profile that may be sensitive to such distribution details.

October 16, 2026

Insiders Buy Into Bluerock Private Real Estate Fund. Recent reports indicate that insiders have purchased shares in the Bluerock Private Real Estate Fund, a move often interpreted as a sign of internal confidence in the fund's outlook. This development provides context for BTX, which is currently trading near its support level with a low RSI, suggesting the stock may be in a corrective phase despite the positive insider activity.

October 1, 2026

ECAT: BlackRock Closed-End Funds Announce Distribution Sources. The trust announced that its closed‑end funds will distribute income from specific sources, giving investors clearer insight into where the cash flow comes from. Knowing the distribution origins can help assess the trust’s stability and potential return. The disclosure comes as the shares trade near a key support level and a low RSI, indicating a possible consolidation phase. Overall, the update adds transparency to the trust’s income profile.

September 25, 2026

BCAT Announces Rights Offering Amid Low RSI. BlackRock Capital Allocation Term Trust has launched a rights offering, a move often used by closed-end funds to raise capital or adjust leverage. This corporate action is the primary driver behind recent market attention for the stock. While the fund trades at a low RSI of 22.1, indicating recent selling pressure, the rights offering represents a significant structural event for shareholders.